Shots:

• The independent DMC has recommended to stop the P-III (KeyVibe-008) study of vibostolimab & Keytruda co-formulation + etoposide & Pt-based CT followed by the co-formulation vs atezolizumab + etoposide & CT followed by atezolizumab as a 1L treatment of ES-SCLC. Patients will be given the option of treatment with atezolizumab
• 1EP of OS reached the futility criteria in a pre-planned analysis, with a higher rate of AEs & immune-related AEs. Complete analysis is underway; data will be shared with scientific community
• Other ongoing P-III lung cancer trials of the combination such as KeyVibe-003, -006 & -007 have undergone interim safety reviews without any study modifications. Comprehensive safety monitoring continues